Msd Merck Co Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MSD MERCK CO, and what generic alternatives to MSD MERCK CO drugs are available?
MSD MERCK CO has five approved drugs.
There are five US patents protecting MSD MERCK CO drugs.
There are one hundred and eighty-nine patent family members on MSD MERCK CO drugs in fifty-one countries and eighty-eight supplementary protection certificates in sixteen countries.
Drugs and US Patents for Msd Merck Co
Expired US Patents for Msd Merck Co
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Merck Co | EMEND | aprepitant | FOR SUSPENSION;ORAL | 207865-001 | Dec 17, 2015 | 6,096,742 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD MERCK CO drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
International Patents for Msd Merck Co Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 108367008 | ⤷ Try a Trial |
Russian Federation | 2445314 | ⤷ Try a Trial |
Norway | 2019019 | ⤷ Try a Trial |
Ukraine | 108495 | ⤷ Try a Trial |
Norway | 336943 | ⤷ Try a Trial |
Croatia | P20040532 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Msd Merck Co Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0736030 | 06C0009 | France | ⤷ Try a Trial | PRODUCT NAME: POSACONAZOLE; REGISTRATION NO/DATE: EU/1/05/320/001 20051025 |
2924034 | C201930027 | Spain | ⤷ Try a Trial | PRODUCT NAME: DORAVIRINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA EN COMBINACION CON LAMIVUDINA Y TENOFOVIR DISOPROXILO FUMARATO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1333; DATE OF AUTHORISATION: 20181122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1333; DATE OF FIRST AUTHORISATION IN EEA: 20181122 |
2666774 | 122020000035 | Germany | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, ODER RELEBACTAM IN FORM DES MONOHYDRATES, UND IMIPENEM; REGISTRATION NO/DATE: EU/1/19/1420 20200213 |
2924034 | 2019018 | Norway | ⤷ Try a Trial | PRODUCT NAME: DORAVIRIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV I KOMBINASJON MED LAMIVUDIN OG I KOMBINASJON MED TENOFOVIRDISOPROKSIL FUMARAT; REG. NO/DATE: EU/1/18/1333/001-2 20181213 |
2552902 | 24/2019 | Austria | ⤷ Try a Trial | PRODUCT NAME: DORAVIRIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1333/001-002 (MITTEILUNG) 20181126 |
2552902 | CA 2019 00025 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/18/1333 20181126 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.